Immunopathogenesis of sarcoidosis and risk of malignancy: A lost truth?

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 2, 2013, Pages 305-313

  Tana, C ^a   Giamberardino, M A ^a   Di Gioacchino, M ^a   Mezzetti, A ^a   Schiavone, C ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer; Lymphoma; Malignancy; Myeloid dendritic cells; Sarcoidosis

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; CYTOKINE;

ANGIOGENESIS; ANTIGEN PRESENTATION; CANCER RISK; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; HEMATOPOIETIC STEM CELL; IMMUNOPATHOGENESIS; INFLAMMATION; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SARCOIDOSIS; TH3 CELL; CANCER INCIDENCE; COHORT ANALYSIS; DISEASE ASSOCIATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; MITOSIS RATE; POPULATION BASED CASE CONTROL STUDY; SELECTION BIAS; T LYMPHOCYTE;

EID: 84881241599     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600204     Document Type: Review

References (33)

1. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305(4):391-9.
2. Tana C, Tana M, Mezzetti A, Schiavone C. Sarcoidosis: old certainties and new perspectives. Ital J Med 2012; 6(3):186-94.
3. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic Sarcoidosis. J Exp Med 2005; 201(5):755-67. (Pubitemid 40395121)
4. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170(12):1324-30. (Pubitemid 39657197)
5. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011; 139(1):174-82.
6. Fischer A, Schmid B, Ellinghaus D, et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Respir Crit Care Med 2012; 186(9):877-85.
7. Zaba LC, Smith GP, Sanchez M, Prystowsky SD. Dendritic cells in the pathogenesis of sarcoidosis. Am J Respir Cell Mol Biol 2010; 42(1):32-9.
8. Grutters JC, Drent M, Van den Bosch JMM. Sarcoidosis. Eur Respir Mon 2009; 46, 126-54.
9. Yoshitomi A, Sato A, Hayakawa H, Chida K, Toyoshima M, Uchijima M, Yoshida A, Koide Y. Biased T cell receptor Vbeta gene expression in bronchoalveolar lavage fluid from Japanese patients with sarcoidosis. Respirology 1999; 4(4):339-47. (Pubitemid 30016281)
10. Alexandrescu DT, Kauffman CL, Ichim TE, Riordan NH, Kabigting F, Dasanu CA. Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J 2011; 17(1):2.
11. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203(2):359-70. (Pubitemid 43290845)
12. Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol 2008; 181(1):746-55.
13. Alexandrescu DT, Riordan NH, Ichim TE, Kauffman CL, Kabigting F, Dutton CT, Dasanu CA. On the missing link between inflammation and cancer. Dermatol Online J 2011; 17(1):10.
14. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011; 81(S):24-9.
15. Zielonka TM, Demkow U, Puscinska E, et al. TNFalpha and INFgamma inducing capacity of sera from patients with interstitial lung disease in relation to its angiogenesis activity. J Physiol Pharmacol 2007; 58(S):767-80.
16. Choi J, Hoffman LA, Sethi JM, Zullo TG, Gibson KF. Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: A pilot feasibility study. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26(2):98-109.
17. Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y. Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 2003; 181(5):259-65. (Pubitemid 37323733)
18. Pabst S, Karpushova A, Diaz-Lacava A, et al. VEGF gene haplotypes are associated with sarcoidosis. Chest 2010; 137(1):156-63.
19. Brincker H. Sarcoid reactions and sarcoidosis in Hodgkin's disease and other malignant lymphomata. Br J Cancer 1972; 26(2):120-3.
20. Yamaguchi M, Odaka M, Hosoda Y, Iwai K, Tachibana T. Excess death of lung cancer among sarcoidosis patients. Sarcoidosis 1991; 8(1):51-5.
21. Brincker H. Coexistence of sarcoidosis and malignant disease: causality or coincidence? Sarcoidosis 1989; 6(1):31-43.
22. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer 1986; 54:467-73. (Pubitemid 16031550)
23. Brincker H. Sarcoidosis and malignancy. Chest 1995; 108(5):1472-4.
24. Kataoka M, Nakata Y, Hioka T, et al. Malignancies in patients with sarcoidosis. Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30(4):598-603.
25. Reich JM, Mullooly JP, Johnson RE. Linkage analysis of malignancy-associated sarcoidosis. Chest 1995; 107(3):605-13.
26. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999; 160:1668-72.
27. Seersholm N, Vestbo J, Viskum K. Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax 1997; 52(10):892-4. (Pubitemid 27473932)
28. Rømer FK, Hommelgaard P, Schou G. Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 1998; 12(4):906-12. (Pubitemid 28491666)
29. Boffetta P, Rabkin CS, Gridley G. A cohort study of cancer among sarcoidosis patients. Int J Cancer 2009; 124(11):2697-700.
30. Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol 2009; 20(6):1121-6.
31. Shu X, Ji J, Sundquist K, Sundquist J, Hemminki K. Survival in cancer patients with previous hospitalization for sarcoidosis: a Swedish population-based cohort study during 1964-2006. Ann Oncol 2011; 22(6):1427-34.
32. Tana C, Iannetti G, D'Alessandro P, Tana M, Mezzetti A, Schiavone C. Pitfalls of CEUS in the diagnosis of splenic sarcoidosis. J Ultrasound 2013; DOI 10.1007/s40477-013-0013-1.
33. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72(4):517-24.